A medication typically used to treat Parkinson’s disease has shown significant promise in reducing symptoms of treatment-resistant depression, according to a major clinical trial led by the University of Oxford.
In the largest study of its kind to date, researchers found that pramipexole, a drug that boosts dopamine levels in the brain, was substantially more effective than placebo when added to standard antidepressant therapy. The findings, published in The Lancet Psychiatry, could mark a turning point for patients who have not responded to conventional treatments.
What Was the Study?
The 48-week double-blind trial, supported by the National Institute for Health and Care Research (NIHR), involved 150 adults with treatment-resistant depression (TRD). Participants continued their regular antidepressant medication and were randomly assigned either pramipexole or a placebo.
By week 12, those receiving pramipexole showed a statistically significant and sustained reduction in depressive symptoms, with benefits lasting through to the end of the year-long study.
What Is Pramipexole?
Pramipexole is a dopamine agonist, commonly prescribed for Parkinson’s disease. Unlike standard antidepressants, which typically target serotonin, pramipexole enhances dopamine activity, a neurotransmitter increasingly linked to motivation and reward processing.
Professor Michael Browning, from the Department of Psychiatry, University of Oxford, and workstream lead in Mood Disorders for the NIHR Mental Health-Translational Research Collaboration (MH-TRC) Mission, who led the trial, said:
“Effectively treating people who have not responded to first-line interventions for depression is a pressing clinical problem and there has long been an urgent need to find new treatments.
“These findings on pramipexole are a significant breakthrough for patients for whom antidepressants and other treatments and therapies have not worked.
“Pramipexole is a medicine licensed for Parkinson’s disease and works by boosting the brain chemical dopamine. This differs from the majority of other antidepressant medications which act on brain serotonin and may explain why pramipexole was so helpful in this study.
Side Effects and Limitations
While effective, pramipexole was not without drawbacks. Around 20% of participants receiving the drug withdrew due to side effects, including nausea, sleep disruption and dizziness.
Professor Browning noted that further research is now needed to:
- Reduce side effect burden
- Evaluate cost-effectiveness
- Compare pramipexole with other add-on treatment options
A Patient’s Perspective
Phil Harvey, 72, from Oxfordshire, had been living with depression for two decades before enrolling in the trial.
“Within a few weeks I felt the effects, it was amazing”, he said “I kept a diary which they gave us on how my mood was, motivation and how it improved. It was dragging me out of this dark black hole that I’ve been in for years.”
Phil had previously tried several medications and counselling approaches without success. His experience reflects the urgent need for new options for people with hard-to-treat depression.
National Research Network
Participants were recruited from across the UK through the NIHR-funded Mental Health Translational Research Collaboration (MH-TRC) Mission—a network of clinics led from Oxford but operating nationwide. These clinics provide streamlined, often remote, assessments for people with complex mood disorders and offer them access to advanced research trials.
This model also supports local NHS services by offering expert treatment advice for patients who have not responded to initial care.
What Does This Mean for Patients?
Current NHS guidelines for TRD often suggest adding lithium or antipsychotic medications to existing antidepressants, options which come with limited effectiveness and notable side effects. Pramipexole could provide an alternative pathway by acting on a different neurotransmitter system.
However, it is not yet licensed in the UK for use in depression, and further trials will be required to secure approval and integration into routine NHS care.
Key Takeaways
- Pramipexole significantly reduces symptoms of treatment-resistant depression
- Works by targeting dopamine, not serotonin
- 1 in 5 participants stopped due to side effects
- Longest and largest study to date on this drug in depression
- Further research needed before clinical adoption
What is pramipexole?
Pramipexole is a dopamine agonist medication typically used to treat Parkinson’s disease. It enhances dopamine activity, which is involved in motivation, mood and reward.
Is pramipexole available on the NHS for depression?
Currently, no. Pramipexole is not licensed in the UK for depression, but these study results may pave the way for future approval.
What are the main side effects?
Reported side effects included nausea, dizziness and sleep disruption. Around 20% of participants withdrew from the trial due to side effects.
How is this different from standard antidepressants?
Standard antidepressants primarily affect serotonin. Pramipexole targets dopamine, potentially offering relief for those who don’t respond to serotonin-based therapies.
